HighVista Strategies has reduced its stake in Maze Therapeutics (MAZE) by selling 70,503 shares in Q1 2026, translating to approximately $3.11 million based on average quarterly pricing, according to a recent SEC filing. Post-sale, HighVista holds 99,850 shares, representing 0.82% of its reported assets under management (AUM).
This divestment comes after Maze Therapeutics’ stock surged around 180% over the past year, significantly outperforming the S&P 500’s 25% gain. Despite the impressive rally, Maze’s shares fell over 30% following the release of promising Phase 2 trial results for its lead kidney disease candidate, MZE829. Investors have expressed concerns about the drug’s competitive viability, even as the company prepares for a pivotal trial in 2027.
For market professionals, this transaction signals HighVista’s strategy to lock in gains while maintaining a position in Maze. The focus now shifts to whether MZE829 can translate early trial success into a viable commercial product amid rising expectations.
Source: fool.com